← The Wire·Breaking·Regulation··2 outlets

Guardant Health ordered to pay royalties after losing patent dispute; shares fall

Guardant Health shares fell after a judge ruled against the company in a patent dispute and ordered it to pay royalties. The ruling adds a legal-cost and intellectual-property overhang to a business still growing revenue but reporting a -42.4% net margin.

STOCK PHOTO · DAVID GUERRERO

The story

The ruling follows a patent dispute involving Guardant Health, with the judge ordering royalties after finding against the company.

The direct exposure is GH, whose FY 2025 revenue was $982.0M, up 32.9% YoY, according to SEC EDGAR data. That growth sits alongside a -42.4% net margin and dilutive EPS of $-3.32, leaving the company financially sensitive to additional obligations.

Key questions include the size and duration of the royalty burden, any impact on product sales or licensing, and whether Guardant appeals the ruling. The market's initial reaction was negative, though the judgment's dollar value and whether operations are materially constrained remain unclear.

Our read · Mon, Aug 24

A judge ordered Guardant Health (GH) to pay royalties after ruling against the company in a patent dispute, adding a legal cost to a business reporting a -42.4% net margin.

Why. The legal overhang matters most because GH is already operating at a -42.4% net margin with dilutive EPS of $-3.32, so an unspecified royalty obligation could further delay the path to profitability. Revenue growth of 32.9% YoY and FY 2025 revenue of $982.0M provide a fundamental offset, but the missing judgment amount prevents a larger directional target.

Both cases

The case it holdsGH's FY 2025 revenue grew 32.9% YoY to $982.0M, giving the company a tangible growth engine that could absorb a limited royalty burden.
The case it breaksThe bear case is stronger on the disclosed facts: a patent loss with court-ordered royalties compounds GH's -42.4% net margin and dilutive EPS of $-3.32, while the amount owed remains unknown.

What could change this view: The trade is impaired if the royalty obligation is immaterial, the ruling is stayed or reversed on appeal, or the company discloses no meaningful impact to products and cash flow.

Guardant Health stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 2

Keep reading

Latest on the Wire

Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on Thursday
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by Yahoo Finance as Guardant Health Dives After Losing A Patent Dispute; Judge Orders Royalties, . Who answers for this

2 reports from 2 publishers in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →